US
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
LANCE Surelight Streptavidin Allophocyanine-Conjugate (Kinase Assay), 50 mg
LANCE Surelight Streptavidin Allophocyanine-Conjugate (Kinase Assay), 50 mg
LANCE standard
Streptavdin-APC for use in LANCE® TR-FRET assays.
| Feature | Specification |
|---|---|
| Application | Protein-Protein Interaction |
Streptavdin-APC for use in LANCE® TR-FRET assays.
Product variants
Unit Size: 1 mg
Part #:
CR130-100
List price
USD 618.00
Your online price:
Unit Size: 50 mg
Part #:
CR130-150
List price
USD 29,843.00
Your online price:
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption, and disposal requirements under European REACH regulations (EC 1907/2006).
LANCE Surelight Streptavidin Allophocyanine-Conjugate (Kinase Assay), 50 mg
LANCE standard
LANCE Surelight Streptavidin Allophocyanine-Conjugate (Kinase Assay), 50 mg
Loading...
Product information
Overview
Revvity offers two versions of SureLight APC-SA: one protein binding assays, and one kinase assays. SureLight APC-SA kinase assays has a ratio of APC:streptavidin that has been optimized to achieve best performance in kinase applications.
Specifications
| Application |
Protein-Protein Interaction
|
|---|---|
| Automation Compatible |
Yes
|
| Brand |
LANCE SureLight
|
| Conjugates |
Streptavidin
|
| Detection Modality |
LANCE
|
| Fluorophore |
SureLight-APC
|
| Product Group |
Fluorescent Reagent
|
| Shipping Conditions |
Shipped in Blue Ice
|
| Target Class |
Binding Assay
|
| Technology |
TR-FRET
|
| Unit Size |
50 mg
|
Resources
Are you looking for resources, click on the resource type to explore further.
Product Info
LANCE and LANCE Ultra TR-FRET technology product list
LANCE™ Ultra TR-FRET is a no-wash proximity assay technology that combines the benefits of time resolution (TR) with fluorescence...
How can we help you?
We are here to answer your questions.
